L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients
| Autor: | M. D. Muenter, Gertrude M. Tyce, K. P. Offord, M. K. Dousa, P. A. Decker, Richard M. Weinshilboum |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Blood Platelets
Male S-Adenosylmethionine medicine.medical_specialty Levodopa Erythrocytes Methyltransferase Catechol O-Methyltransferase Methylation chemistry.chemical_compound Sulfation Biotransformation Internal medicine medicine Humans Biological Psychiatry Aged Catechol-O-methyl transferase Dose-Response Relationship Drug Sulfates Carbidopa Parkinson Disease Metabolism Middle Aged Arylsulfotransferase nervous system diseases Adenosine Diphosphate Drug Combinations Psychiatry and Mental health 3'-Phosphoadenosine-5'-phosphosulfate Dose–response relationship Endocrinology Neurology chemistry Female Neurology (clinical) medicine.drug |
| Zdroj: | Journal of Neural Transmission. 110:899-910 |
| ISSN: | 1435-1463 0300-9564 |
| Popis: | The objectives of this study were to determine (1) the effects of dose and drug absorption on pathways of biotransformation of L-DOPA in Parkinsonian patients treated with Sinemet, and (2) the extent to which genetically-determined variations in the activities of erythrocyte catechol O-methyltransferase and/or platelet phenol sulfotransferase might be reflected in individual differences in L-DOPA metabolism. In the 19 patients studied, there were negative correlations between dosage or absorption and extent of O-methylation and of sulfation of L-DOPA or its metabolites. Levels of activity for erythrocyte COMT were also reflected in individual variation in the metabolism of L-DOPA. In contrast, differences in platelet phenol sulfotransferase were not reflected in differences in sulfation of L-DOPA or of its metabolites. If such a relationship did exist, it might have been obscured by the effects of high dosage of L-DOPA, effects which might have resulted from a deficiency of the sulfation cosubstrate 3'-phosphoadenosine 5'-phosphosulfate in patients taking higher doses of drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink